Australia's TGA issues interim report to remove supplements high in B6 from shelves as toxicity cases rise
Vitamin B6 — often listed as pyridoxine, pyridoxal, pyridoxamine — is present in thousands of products in Australia as an additive, including medicines, multivitamin and mineral supplements, energy drinks and weight loss shakes.
174 reports of peripheral neuropathy, peripheral sensory neuropathy, small fibre neuropathy or chronic polyneuropathy for products containing B6 have been reported to the medicines' regulator, the Therapeutic Goods Administration (TGA), though medical practitioners predict the true number is significantly higher.
"While most of them have no side effects, if you are taking large doses of B6 your risk of peripheral neuropathy goes up."
"We know that reported cases of peripheral neuropathy are a massive underestimate of the problem in the community, because so many people are unaware that that vitamins can cause these symptoms."
In a new development to improve public safety, several recommendations have been handed down in a report penned by a senior TGA medical officer known as 'the delegate'.
Called the 'Interim Decision', the report acts on the advice of the government's Advisory Committee on Medicines Scheduling.
Most notably, it calls for the TGA to reclassify supplements containing more than 50mg of B6 as Schedule 3 (Pharmacist Only), by February 2027.
The move would affect around 100 products, requiring pharmacists to first speak with consumers before approving a purchase.
"Currently, preparations providing up to 200 mg of [B6] ... are available for self-selection without any professional guidance or oversight," the report states, adding "almost 80 per cent of these products provide a dose of more than 2 mg/day, which is above the RDI for pyridoxine, pyridoxal or pyridoxamine.
"The daily requirement of vitamin B6 can be easily obtained from the usual Australian diet, and the use of supplemental vitamin B6 provides limited benefit except in people who have a clinically diagnosed vitamin B6 deficiency.
A TGA spokesperson told 7.30 the decision, if implemented, "will reduce the maximum amount of vitamin B6 allowed in oral products than currently available for general sale".
"The interim decision balances the risks and benefits of using vitamin B6 including the risk of peripheral neuropathy, acknowledging its potential for irreversible harm at higher doses and variability in individual metabolism," the spokesperson said.
But, as detailed in the report, the proposed changes only account for around seven per cent of supplements containing B6 — there are more than 1,500 vitamins listed on the Australian Register of Therapeutic Goods, the majority of which are unscheduled and available over the counter.
The report also recommended supplements exceeding 200mg should be reclassified as prescription medicines or 'schedule 4'.
"It's a good thing that pharmacists will be able to have a really good counselling session with a patient, to make sure the item they're taking doesn't interact with other medications," said Caroline Diamantis, vice-president of the Pharmaceutical Society of Australia.
"People used to think that complimentary medicines were completely safe but the more we delve into it the more we understand they do have unwanted side-effects or interference with other medications," she told 7.30.
The interim decision also recommends tightening labelling rules, calling for clearer identification of vitamin B6 on packaging and stronger warnings to help consumers avoid accidental overexposure.
"Use of ingredient names in labelling is inconsistent and confusing for consumers … and not always described as vitamin B6," the report said.
"Of concern is that there are several products on the market where the front of the label provides no indication that vitamin B6 is an ingredient."
It suggested changing the language on warning labels to be more direct.
"Excess consumption of vitamin B6 can cause nerve damage. Stop use and see a doctor if you experience tingling, burning or numbness," was a suggestion.
The report also calls on the multi-billion-dollar complementary medicines sector to take greater responsibility for educating consumers and reducing the risk of vitamin B6 overexposure, noting current labelling places too much burden on consumers to calculate total B6 intake.
"Estimating the total daily vitamin B6 intake … is likely to be beyond the health literacy capability of the typical consumer," it said.
The CEO of Complementary Medicines Australia John O'Doherty told 7.30: "we'll be carefully reviewing the interim decision and the recommendations of the Advisory Committee on Medicines Scheduling."
Mr O'Doherty argued adverse events relating to the use of vitamin B6 are "extremely rare".
"Based on a comparison of sales data with the TGA's public Database of Adverse Events, the chance of a reaction is less than one in half a million — this is extremely rare," he said.
However, previous 7.30 investigations have found dozens of Australians have had issues from B6 toxicity, with many only becoming aware of their illness after seeing our reports.
The TGA delegate also warns the prevalence could be much higher.
"The true rate of occurrence of an adverse event cannot be determined from spontaneous adverse event reporting systems due to both general under-reporting and a lack of usage data," its report read.
"A low number of spontaneous adverse event reports cannot be considered evidence of the absence a safety issue."
Mr O'Doherty however agreed with some of the labelling recommendations, telling 7.30 his organisation has "been calling on the TGA to implement changes that allow labels and advertising to use terminology and ingredient names that consumers better understand."
"At CMA's request, this is now under internal review at the TGA", he said.
Medical negligence lawyer Nick Mann said the interim decision is a "small step in the right direction" but argued the TGA "can and should" go further.
Mr Mann told 7.30 his legal firm, Polaris, is pursuing a class action lawsuit against one of the largest companies in the complementary medicines industry, Blackmores, "as a matter of public interest and safety".
"We continue to investigate the potential class action, and given the response, the support and the evidence that's been pouring in ... with over 140 people contacting us to date," Mr Mann said.
"Each of them had heartbreaking stories about how their lives have been affected by B6 toxicity, and sadly, many of them continue to be affected long after ceasing supplements containing Vitamin B6.
"We've also had at least 10 doctors contact us to tell us about their own experiences with B6, and to let us know that they have discovered B6 toxicity in several of their patients, after taking supplements containing higher than the RDI of the vitamin over weeks and months," he said.
The interim decision recommends the changes be made by 1 February 2027 — offering an 18-month implementation period.
Watch 7.30, Mondays to Thursdays 7:30pm on ABC iview and ABC TV
Do you know more about this story? Get in touch with 7.30 here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
an hour ago
- ABC News
Disability advocates say NDIS changes disregard alternative therapy benefits
On the red dirt in the outskirts of Kalgoorlie in Western Australia, a large, dark bay horse gently nuzzles Cooper in the chest. The 16-year-old in a wide-brim cowboy hat smiles. It is a sweet moment between the two friends. Cooper remembers being sceptical when his parents first suggested equine therapy as a way to build confidence and better manage his emotions during a difficult period. But he gave it a go. And the results, he says, have been life-changing. "It helps regulate my emotions. "When you're in control of such a big animal, it makes the other big things in life seem less scary." In his first equine therapy session, Cooper bonded with a horse named Rio. "Rio's the biggest and scariest," he said. "He weighs over half a ton. "They say he has ADHD (attention deficit hyperactivity disorder), which is OK because I do too." Now, as Cooper gently brushes Rio under the dappled shade of a gum tree, both seem very serene. Cooper, who also has autism, accessed equine therapy through the National Disability Insurance Scheme (NDIS). However, that stopped in October when the federal government introduced significant changes to the NDIS to reduce costs, including no longer funding equine therapy. Peak disability advocacy bodies have told the government some of the new rules are too "medicalised" and don't consider the benefits of some alternative therapies. The feedback was part of a consultation period on the new NDIS Support rules, open for public submissions until July 27. The NDIS Support rules list what is and is not funded. You can read it here. One of the major changes is that the NDIS will no longer fund supports that are not "evidence-based" or directly linked to someone's disability. Equine therapy falls under the umbrella of animal therapies, which are activities designed for people to have a positive experience with animals. It can include things like rabbit petting, playing with puppies or horse riding. Often, the goal is to help people cope with or recover from mental and physical health conditions, but it can vary. Under the changes, animal therapy has been deemed an "alternative" or "complementary therapy" and now falls in the same excluded category as tarot card reading, aromatherapy and crystal therapy. Assistance animals, like guide dogs, that are specially trained to help someone manage a disability, remain funded. As does animal-assisted therapy, which is where an accredited therapist uses an animal to help clients engage in therapy and get the most out of their sessions. Music and art therapy also remain funded by the NDIS, as long as the therapists are registered with the relevant peak bodies, which require them to have undergone recognised training and accreditation. In May, the government held online consultation sessions with disability peak bodies around the NDIS Support rules. A summary document of the feedback says there is evidence some supports no longer funded by the NDIS, like (alternative) therapies, work well for people with disability, where it meets their needs. "Participants particularly spoke about therapies. They said the lists are 'medicalised' and do not consider the benefit of some alternative therapies to participants." Other feedback included that remote communities need to be considered separately from metropolitan areas. "There are gaps in services in rural and remote communities that means more flexibility is needed." The Department of Social Services (DSS), which is running the consultations, says the feedback will help make decisions about what supports will and won't be funded in the future. People with Disability Australia was one of the peak advocacy organisations to contribute to the May round of consultation. Acting chief executive Megan Spindler-Smith said there were concerns the lists were too medicalised and too focused on being evidence-based. "This drive to be evidence-based is important, but what it means is that a lot of things like alternative therapies we know work in specific cases, or for some groups of people with disability, are not able to be considered," they said. Mx Spindler-Smith said the term "evidence-based" was also problematic because people with disability had historically not been allowed to take part in research, particularly clinical research. "So then that evidence doesn't necessarily link exactly to our direct lived experience." Another concern, Mx Spindler-Smith said, was the lack of consideration and flexibility for those living in non-metropolitan areas to access funded support services. "Registered therapists don't necessarily have a home base in many regional and remote areas," they said. "Which means that there are cohorts that are never going to be able to access it in the same way and therefore have been using non-registered therapists or people who can provide a similar level under supervision but cannot be seen as part of the list." Mx Spindler-Smith said it was important those in the disability community shared their views and experiences. "Right now, there is an opportunity until July 27 for you to have your say," they said. Lynette Keleher is the owner and operator of Breakthrough Equine Therapy, where Cooper does his lessons. Ms Keleher said Cooper was just one of hundreds of young people on the NDIS she had seen benefit from equine therapy over the years. She likened it to learning a new language or musical instrument in terms of how it engaged the body, brain and emotions. "We have a retainment rate of 90 per cent. Week after week, our clients return eager to see their favourite horse and reconnect. "You can see their troubles, negative thoughts and self-doubts disappear." Ms Keleher said previously, the business had about 50 per cent NDIS clients but had to pivot to offering other services when the changes came into effect. She said the financial impact meant a reduction in the number of staff — many of whom were NDIS participants employed through Breakthrough. Kalgoorlie-Boulder resident Jo Russell said her 21-year-old daughter Megan, regularly attended the equine therapy sessions at Breakthrough. "The gains she had made — it matched up with her NDIS goals. It aligned with what we were trying to develop and create for her and with that little stroke of the pen … it's all gone." Megan Russell requires full-time care. She is non-verbal, has autism, an intellectual disability and hip dysplasia. Her mother, Jo Russell, said the equine therapy sessions had both psychosocial and physical benefits. The physical benefits came from sitting up straight in the saddle and riding, which improved her daughter's mobility, posture and flexibility. And the psychosocial benefits, Ms Russell said, came from feeding and grooming horses, and interacting with staff, which helped break down the interpersonal gaps that came from her autism and avoiding contact. Ms Russell said continuing with the sessions, without the support of the NDIS, was not financially feasible. "[My daughter] is on a disability support pension. I'm on a disability support pension. I couldn't afford it for her, she couldn't afford it for herself," Ms Russell said. Ms Russell said she had heard similar stories from other members of the Goldfield region's disability community. "They're all very distressed because some of them can see their children regressing," she said. "The gains that have been made [through equine therapy], have now been lost." Ms Russell said the changes disproportionately affected regional and remote communities, like Kalgoorlie-Boulder, which struggled to attract and retain experienced specialists and health professionals. Psychologist and animal-assisted therapy expert, Professor Pauleen Bennett, said while there could be benefits to activities like equine therapy — the term "therapy" was misleading and the lack of regulation and oversight had the potential to cause harm. Professor Bennett said the alternative could be damaging and meant people might be missing out on real therapy with a qualified therapist. "For me, the critical difference is whether it's therapy or whether it's something else," she said. "That doesn't mean we shouldn't be doing it, and maybe the NDIS needs to be looking as some sort of way of accrediting people or organisations who do animal-assisted activities, but without calling it therapy," she said. Without the proper checks and balances that existed for other allied health services, Professor Bennett said anyone could claim to provide animal therapy — and there was no way for people to know whether it was fantastic or terrible. "We need some way of ensuring that the activities that they're doing are having a positive benefit," she said. "For some people, they definitely are. But without some sort of quality control … it's difficult to know." Meanwhile, Cooper and his family will be watching the outcome of the NDIS Support rules review closely. The Kalgoorlie teenager has not stopped equine therapy sessions entirely, but without the support of NDIS funding, they say visits will be fewer and far between.

ABC News
an hour ago
- ABC News
Prescriptions to be issued by WA pharmacists for asthma, ear infections under training program expansion
Pharmacists in Western Australia now have the opportunity to expand what they can prescribe in a bid to ease pressure on the state's health system. The WA government has announced the expansion of a pilot program offering further training for pharmacists, allowing them to diagnose and treat health conditions that would normally require people to visit a GP. The expanded pilot program will allow pharmacists to treat certain skin conditions, ear infections and asthma. Currently pharmacists can treat urinary tract infections, re-supply oral contraceptives and administer certain vaccines. WA Health Minister Meredith Hammat announced the program's expansion on Monday, saying it would provide people with more options to access health care. "By enhancing the skills of community pharmacists, we are reducing pressure on hospitals and GPs while giving patients safe, effective care options closer to home," Ms Hammat said in a statement. "GPs will continue to play a really important role in the healthcare system," she later told reporters on Monday. Ms Hammat said during consultation, the Australian Medical Association and the College of Royal General Practitioners had raised concerns about the program. "Our focus is on making sure the program is safe and effective," she said. The qualification will be issued by universities and is expected to take 12 months to complete, with graduates receiving a certificate in pharmaceutical prescribing.

News.com.au
5 hours ago
- News.com.au
Hot Money Monday: Proteomics brings science to racehorse recovery, as animal health booms
New blood test reveals hidden muscle damage in racehorses Proteomics' OxiDx helps trainers spot injuries early and avoid breakdowns ASX-listed stocks with exposure to the animal sector. In the high-octane world of thoroughbred racing, muscle is money. Every gallop, every second shaved off the clock comes down to conditioning, training, and recovery. But what happens when something breaks, and you don't even know it? That's the riddle Proteomics International Laboratories (ASX:PIQ) and its subsidiary OxiDx are solving with a groundbreaking new test that can detect muscle damage in racehorses. Last Monday, Proteomics announced a major update. Its patented OxiDx test has now proven – via peer-reviewed research – that it can track oxidative stress and pinpoint muscle injury in thoroughbred racehorses post-race. In short: trainers and vets now have hard data instead of relying on gut feel. Published in Veterinary Medicine and Science, the study tracked 34 Australian racehorses across seven days after racing. Using a dried blood spot from each horse, the OxiDx test measured thiol-oxidised albumin, a protein biomarker of oxidative stress. The findings were clear: oxidative stress levels peaked two days after a race and stayed elevated for up to five. Some horses took even longer to recover. That variability suggests that one horse might bounce back after 48 hours, while another might still be nursing invisible damage a week later. And if you're a trainer pushing too hard, too soon, that kind of hidden strain can lead to breakdowns. In fact, up to 85% of thoroughbreds suffer at least one injury during their early racing years, many of them muscle-related and many going undiagnosed until it's too late. OxiDx redefines racehorse recovery What makes this test so compelling is its simplicity. Forget MRI scans or expensive ultrasounds, and forget relying on subjective gait assessments or enzyme tests. This is a world-first blood test. Non-invasive, stable, and gives trainers and vets something they've never had before: objective insight into how a horse is actually recovering. 'These exciting results mark a significant milestone in applying the OxiDx test to equine veterinary medicine,' said Proteomics' CEO, Dr Richard Lipscombe. 'OxiDx has the potential to empower trainers to monitor muscle recovery with precision, helping their racehorses achieve peak performance while prioritising equine health and well-being.' This is all about protecting high-value assets. After all, elite racehorses are routinely valued in the millions, and breeding stallions commanding even higher figures. OxiDx seems to have a first-mover foothold in this lucrative corner of the market. If all goes to plan, PIQ said the OxiDx test could be hitting Aussie stables by this time next year, potentially becoming a go-to tool for trainers. Animals are serious business While most of the world has its eye on human medicine, the animal health sector has been galloping ahead, quietly becoming one of the hottest areas in biotech. If you dig into the numbers, animal diagnostics is a actually billion-dollar market that's been growing faster than many areas of human healthcare. The market is driven by rising pet ownership and humanisation, growing demand for livestock productivity, and in this case, the high economic value of performance animals. It's serious business, especially when the animals in question are worth more than most houses. Other animal-relates stocks on the ASX Apiam Animal Health (ASX:AHX) Apiam is Australia's biggest rural and regional vet group, with boots on the ground from dairy farms to dog parks in over 70 locations nationwide. It's got 330-plus vets and a serious logistics backbone - warehouses in four states, national lab networks, and even eCommerce for livestock producers. And now, Apiam is rolling out CoVet, an AI-powered clinical tool that's already making traction in its network. Using voice recognition and smart templates, CoVet takes care of the boring stuff like generating notes and discharging instructions so vets can spend less time typing and more time treating. In June, Apiam appointed seasoned executive Bruce Dixon as interim managing director, following the departure of founding CEO Dr Chris Richards. Mad Paws (ASX:MPA) Mad Paws is Australia's go-to marketplace for pet care, connecting pet owners with trusted sitters, walkers, groomers, and a growing range of pet products and services. Launched in 2014, the company was built to solve the age-old question: 'What do I do with my pet when I'm away?' With 73% of Aussie households already owning pets, and spending over $3,000 per year on dogs alone, the market is big, sticky, and recession-resistant. And with consumer trends like pet humanisation on the rise, Mad Paws could be positioned to ride the wave. Aroa Biosurgery (ASX:ARX) While not directly in the pet or animal business, Aroa's use of ovine tissue put it in a unique position at the intersection of animal-derived innovation and human health. The New Zealand-born medtech company uses something pretty special to help the human body heal - tissue from the forestomach of sheep. Led by vet-turned-founder Dr Brian Ward, Aroa discovered that ovine tissue, particularly the extracellular matrix (ECM), closely mirrors human soft tissue and is packed with over 150 proteins vital to healing. After carefully stripping the tissue of cells and DNA, what's left is a natural scaffold that guides the body to regenerate itself, helping tissue repair in complex wounds. With FDA approvals, global distribution across 50+ countries, and standout clinical results, the company is hitting its stride. At Stockhead we tell it like it is. While Aroa Biosurgery is a Stockhead advertiser at the time of writing, it did not sponsor this article.